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Abstract
Purpose: The purpose of this study is to demonstrate that the expression of rhodopsin can be down regulated in vivo by AAV-deliv-
ered siRNA. This is the Wrst step in an RNA replacement strategy for the allele-independent treatment of Autosomal Dominant Retinitis
Pigmentosa (ADRP).
Methods: HEK 293 cells were co-transfected with a plasmid carrying mouse RHO cDNA driven by the CMV promoter and a chemi-
cally synthesized siRNA duplex of 21 nucleotides. Reduction of RHO mRNA was conWrmed by RT-PCR. One active siRNA and a con-
trol siRNA were embedded in a small hairpin RNA (shRNA) and cloned in Adeno-associated virus (AAV) vector under regulation of the
H1 promoter and containing a GFP reporter. AAV5 expressing either active siRNA or an irrelevant siRNA were subretinaly injected into
the right eyes of wild-type or RHO+/¡ heterozygote mice at post-natal day 16. At 1 and 2 months post-injection, animals were analyzed
by electroretinography (ERG). Animals were then sacriWced, and retinas were examined by Western blot, RT-PCR, histology and immu-
nohistochemistry.
Results: All of the siRNAs tested in HEK 293 cells caused degradation of RHO mRNA, although the eYciency varied from 25% to
80%. In vivo siRNA delivery to the retina led to more than 40% reduction of scotopic a- and b-wave amplitudes in RHO+/¡ heterozyg-
otes. Although the reduction of RHO mRNA was estimated at 30% compared to control animals, Western blots revealed 60% decrease in
rhodopsin content. Histological analysis showed signiWcant reduction in the thickness of the ONL, ranging between 53% and 86%.
Conclusions: AAV-siRNA delivery into the subretinal space resulted in the reduction of retinal function caused by diminished RHO
mRNA and protein content. This level of reduction may permit the replacement of endogenous mRNA with siRNA-resistant mRNA
encoding wild-type RHO.
© 2006 Elsevier Ltd. All rights reserved.
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Retinitis pigmentosa (RP) is an heterogeneous group of
diseases clinically characterized by loss of the night vision
followed by progressive loss of peripheral vision (Krauss &
Heckenlively, 1982). The disease is caused by heritable
defects in rod photoreceptor cells or the RPE (retinal pig-
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doi:10.1016/j.visres.2006.11.026ment epithelium) cells and may be transmitted in an auto-
somal dominant (ADRP), autosomal recessive (ARRP) or
X-linked (XLRP) fashion. Over 120 mutations in the RHO
gene, which encodes rhodopsin, have been identiWed. The
majority cause ADRP.
Gene therapy for ADRP can adopt a direct or an indi-
rect strategy. Indirect approaches support the survival of
rod cells without aVecting expression of the mutated pro-
tein. For example, neurotrophic factors like GDNF
(McGee Sanftner, Abel, Hauswirth, & Flannery, 2001) and
antiapoptotic proteins such as XIAP (Petrin et al., 2003)
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of photoreceptors. The direct approach involves modulat-
ing relative levels of mutant and wild-type protein. The
study of dominant negative forms of RP, often associated
with toxicity of mutated RHO, suggests that the mutant
gene must be repaired or silenced. Two strategies have been
proposed for RHO mRNA silencing. The Wrst includes the
use of allele-speciWc inhibitors, which block the expression
of only the defective mRNA and allow expression of the
normal allele. Expression of only the wild-type allele should
be suYcient to maintain the function of surviving rod cells
(Liang et al., 2004). To be widely applicable, however, the
considerable heterogeneity among RHO mutations would
likely require the development of a large number of muta-
tion-speciWc inhibitors. The second strategy takes an allele-
independent approach: antisense agents are designed to
suppress all RHO alleles, mutant and wild-type (Farrar,
Kenna, & Humphries, 2002). Therefore, allele independent
RNA inhibitors are more useful, since a single reagent can,
in theory, be used against diVerent alterations in the RHO
gene. For optimal therapy, they should be used in combina-
tion with wild-type cDNA containing silent mutations that
block base pairing with the antisense inhibitor.
A variety of such antisense inhibitors are available. These
include small catalytic RNA (ribozymes), antisense oligonu-
cleotides, small interfering RNA (siRNA) and antisense tran-
scripts that regulate alternative mRNA splicing (Alfano
et al., 2005). It has already been established that ribozymes
can limit gene expression by cleavage of targeted mRNA in
the retina (Drenser, Timmers, Hauswirth, & Lewin, 1998;
Gorbatyuk, Pang, Thomas, Hauswirth, & Lewin, 2005;
Lewin et al., 1998). Despite this successful application of
ribozymes in vivo, many researchers consider siRNA a more
potent and more durable approach. It has been estimated
that the half-maximal inhibition levels of siRNA are some
100- to 1000-fold lower than an optimal antisense oligonu-
cleotide directed against the same target (Miyagishi, Hayashi,
& Taira, 2003). Several experiments suggest that RNA inter-
ference using siRNA is also more eVective than ribozymes or
DNAzymes (Akashi, Matsumoto, & Taira, 2005; Yokota
et al., 2004). Small interfering RNAs can be used in an allele
independent approach for ADRP gene therapy. For exam-
ple, Kiang et al. have designed siRNAs targeting the RHO
gene and created a resistant RHO gene with seven mis-
matches to replace the native one (Kiang et al., 2005). They
demonstrated in tissue culture experiments that the modiWed
RHO mRNA was resistant to siRNA-mediated attack, even
at high concentrations of the siRNA. In vivo RNA interfer-
ence has been used to reduce the expression of growth factors
in the retina, suggesting that this approach should be appli-
cable if the correct siRNA and delivery system are employed
(Kwak, Okamoto, Wood, & Campochiaro, 2000; Nakamura
et al., 2004; Reich et al., 2003; Saishin et al., 2003). Small
interfering RNA can be processed from small hairpin RNA
(shRNA) driven by an RNA pol III promoter like U6 or by a
pol II promoter like CMV (Xia, Mao, Paulson, & Davidson,
2002).Only just recently has RHO directed gene therapy been
attempted in the retina using siRNA (Tessitore et al., 2006).
In their study, Tessitore et al., used AAV5 containing the
U6 promoter to deliver an shRNA preferentially targeting
the mouse P23H RHO transgene. Expression of this allele-
speciWc siRNA reduced the mutant RHO mRNA in P23H
line 3 rats and, presumably, should have decreased the level
of P23H rhodopsin. However, suppression of the P23H
RHO allele did not lead to the rescue of vision in these
transgenic animals. The authors concluded that more
robust shRNA expression in the retina may be required to
achieve therapeutic eYcacy in vivo.
In the current study, instead of targeting a speciWc
mutant allele we designed shRNA molecules that would
cause degradation of both wild-type and mutant alleles of
RHO. We used the H1 promoter system and AAV serotype
5 to transfer genes for short hairpin RNAs acting as a pre-
cursor for RHO-speciWc siRNAs. Our goal was to demon-
strate that the expression of RHO, the most abundant
retinal protein, can be down-regulated by AAV-delivered
siRNA to the retina. This is the Wrst step in an RNA
replacement strategy for the allele-independent treatment
of ADRP, requiring, as a second step, supplementation
with an siRNA-resistant RHO to retinas treated with
siRNA.
2. Materials and methods
2.1. Design and screening of siRNAs in cultured cells
We designed siRNAs targeting the mouse RHO coding sequence based
on recommendations described by Jagla et al. (2005). The targets of the
siRNAs comprised of 19 nucleotides of the mouse RHO gene (Table 1).
Some siRNA targets were conserved between mouse and human or mouse
and dog RHO mRNA. These target sequences were used to screen Gen-
Bank using BLAST to avoid possible oV-target eVects in the mouse.
Duplexes of the designed siRNAs were purchased from Dhramacon, Inc.
(Lafayette, CO). The numeration of all siRNAs came from the location of
the targeting segment on RHO mRNA sequences.
To test siRNAs in vitro, HEK 293 cells were co-transfected with syn-
thetic siRNAs and with plasmids expressing mouse RHO driven by the
CMV promoter. An irrelevant siRNA (targeting a cardiac-speciWc
mRNA) was used as a control. Transfection of HEK 293 cells, RNA
extraction and quantitation of RHO mRNA by RT-PCR was performed
as described in an earlier publication (Gorbatyuk et al., 2005).
2.2. rAAV-siRNA constructs
For delivery and prolonged expression in animal tissues, siRNA genes
were inserted into pSilencer plasmid (Ambion) under control of the H1
RNA polymerase III promoter and an oligoT terminator sequence. The
expression cassette was then cloned into the Sal I sites of AAV2 vectors
Table 1
RHO siRNA target sequences
siRNA Targeted region in RHO sequence SpeciWcity
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enhancer/chicken -actin (CBA) chimeric promoter (Fig. 2). This vector
was packaged in AAV5 capsids, which have been shown to lead to more
rapid and robust transduction of photoreceptor cells than AAV2 (Auric-
chio & Rolling, 2005; Rabinowitz et al., 2002). Infected cells expressing
both the siRNA and GFP could be monitored by GFP Xuorescence.
2.3. Subretinal vector injection
Mice were treated in accordance with the policies of the University of
Florida IACUC and in compliance with the ARVO Statement for the Use
of Animals for Ophthalmic and Vision Research. The siRNA vector was
tested in heterozygous RHO knockout mice (RHO+/¡) and C57BL/6J
(RHO+/+). Heterozygous mice were created by crossing C57BL/6
(RHO+/+) mice with RHO knockout mice (RHO¡/¡). The RHO knock-
out mice were generated by disruption of both opsin alleles (Lem et al.,
1999) and were a generous gift of Dr. J. Lem.
Mice were injected subretinally in their right eyes at post-natal day 16
(P16) with AAV5 siRNA301 or AAV5 expressing an irrelevant siRNA
(speciWc for cardiac phospholamban mRNA, GenBank gi:257745). Both
siRNAs were cloned and packaged identically. The subretinal injection
method was described by Timmers, Zhang, Squitieri, and Gonzalez-Pola
(2001). 0.5 l of AAV5-ribozyme (1.3 £ 1012 vector genomes) was injected
subretinally into the right eyes of RHO+/¡ mice. Left eyes served as an
untreated control. A single cohort of animals of each genotype was used
for ERG analysis (see below) at 1 and 2 months and for analysis of rho-
dopsin mRNA and protein content at the end of the experiment.
2.4. Visual function tests
For ERG analysis, mice were dark-adapted overnight, and scotopic
ERGs, which primarily measure rod function, were elicited with 10 s
Xashes of white light at intensities of 0.02, 0.018 and 2.68 cd s/m2. Five
Xashes were averaged at each light intensity. Details of analysis are
described in Gorbatyuk et al. (2005).
2.5. Isolation of total RNA for quantitative analysis of RHO 
mRNA
Total RNA was isolated from each retina with an RNAqueous isola-
tion kit (Ambion) following the manufacturer’s procedure. Isolated RNA
was treated with DNAse I (Ambion) to remove genomic DNA contamina-
tion. Quantitative RNA analysis was performed by comparison of RHO
and -actin ampliWcation products from right and left eyes of individual
mice (Gorbatyuk et al., 2005). The amount of RHO mRNA in a total
RNA sample was normalized to the level of -actin PCR product in each
sample using Sybr-Green staining.
2.6. Protein analysis
Individual retinal protein extracts were obtained from dissected retinas
by sonication in Laemmli loading buVer. Ten micrograms of total retinal
protein was used in each lane. Protein samples were separated by electro-
phoresis on 12% SDS–polyacrylamide gels. Then proteins were transferred
to a nitrocellulose membrane, which was incubated overnight with a pri-
mary antibodies. As a primary antibody against opsin, we used the B6-30
antibody (a gift from Dr. Paul Hargrave). As an internal control, -actin
was detected by anti--actin antibody (Sigma–Aldrich). Detection of pro-
tein-primary antibody complexes was done with alkaline phosphatase-
conjugated secondary antibodies. The complexes were visualized using the
color reagent, 5-bromo-4-chloro-3-indolyl phosphate (Zymed Inc.) and
band intensities were analyzed using the Bio-Rad Gel Analysis Software.
2.7. Histological and immunohistochemical analysis
Eyes were Wxed in 4% paraformaldehyde overnight at 4 °C. Eye cups
were then transferred into phosphate buVered saline and submergedsequentially in solutions of 10%, 20% and 30% sucrose. Eye cups were then
embedded in OCT medium (Sakura Finetek, Inc.) in order to produce
12 m frozen sections. The frozen sections were used to measure the outer
nuclear layer (ONL) thickness as an indicator of treatment-induced retinal
degeneration. Sections of mouse retina Wxed as described above were
stained with propidium iodide. Images were taken on a Zeiss Xuorescent
microscope (Axiovert 200) for full retina mapping retina, and 400 m
radial sections, starting from optic nerve (ON), were used to count the
ONL lengths by using Axiovision 4.4 Software. Immunostaining with B6-
30 antibody was conducted to detect RHO protein. Detection of RHO was
done by secondary antibody conjugated with CY5(Jackson Lab Immuno-
research Co).
2.8. Statistical analysis of data
Student’s t-test for paired data was employed to test signiWcance of
ERG, protein and RNA measurements. Results were expressed as means
with standard error of the mean (SEM). Data from ERG and RNA analy-
sis are presented as the average of the ratios of the injected eye versus
uninjected eye in each animal injected with AAV5 expressing siRNA301
or AAV5 expressing an irrelevant siRNA. Protein analysis results were
expressed in the direct measurement of right and left eye samples. For
comparison of the ONL thickness, results were examined using the one-
way ANOVA test.
3. Results
3.1. Screening of siRNA in cultured cells
All siRNAs (301, 589, 750 and 855) were designed to
degrade mouse RHO mRNA, with the exception of siR-
NA301 which also targets dog and human RHO (Table 1).
Co-transfection experiments in HEK 293 cells showed
that each of the siRNAs could cause degradation of
RHO mRNA, although the level of eYciency varied (Fig. 1).
SiRNA549 showed about 25% reduction of RHO mRNA,
siRNA301 and siRNA750 resulted in 50% of mRNA
reduction, while siRNA855 demonstrated 80% knock down
of RHO mRNA compared to an irrelevant siRNA. This
siRNA eYciently suppresses the synthesis of cardiac
Fig. 1. siRNA leads to RHO mRNA degradation in vitro. HEK 293 cells
were transfected with a plasmid expressing the mouse RHO gene using the
CMV immediate early promoter and duplexes of an irrelevant siRNA
(against phospholamban[PLN]), siRNA301, siRNA549, siRNA750 or
siRNA855 targeted against RHO mRNA. The high eYciency of the irrele-
vant siRNA was shown in vitro in neonatal rat cardiomyocytes by Andino
et al. (manuscript in preparation). Levels of RHO transcript were mea-
sured in triplicate using reverse transcription polymerase chain reaction
(RT-PCR) and were normalized to levels of -actin mRNA ampliWed in
the same reactions. Products were analyzed as described previously
(Gorbatyuk et al., 2005).
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cytes (Andino et al., manuscript in preparation). Despite
the fact that siRNA301 reduced mouse RHO mRNA by
only 50%, we proceeded to test this inhibitor in mice, since
it could also be tested in a large animal model of ADRP as
a prelude to clinical testing.
3.2. Delivery of siRNA to the subretinal space
Delivery of siRNA into subretinal space was accom-
plished by cloning the siRNA sequence in AAV as a small
hairpin RNA (shRNA) under the control of the H1 pro-
moter (Fig. 2). Delivery was veriWed by detection of GFP,
which was co-expressed in this vector using a chimeric
CMV enhancer-CBA promoter (Fig. 2). Transduction
extended over 80% of the retina, and expression was
restricted to photoreceptor cells. However, not all photore-
ceptors were infected and, in many animals, the inferior
hemisphere was preferentially transduced (data not shown).
Mice heterozygous for a disruption of the RHO gene
(RHO+/¡) and wild-type CB57BL/6 mice (RHO+/+) were
injected subretinally in their right eyes at P16 with AAV5
siRNA301, AAV5 expressing an irrelevant siRNA.
3.3. Attenuation of a- and b-wave amplitudes of ERG in 
response to AAV5 siRNA301
Animals were analyzed by full-Weld scotopic electroreti-
nography (ERG) at 1 and 2 months after injection. AAV
expressing siRNA301 caused a modest but statistically
insigniWcant reduction in the ERG response of treated eyes
in RHO+/+ mice at 1 and 2 months after injection (for
a- and b-waves amplitudes p values <0.08 and 0.2 and 0.08
and <0.12, respectively) (Fig. 3a). This observation was sim-
ilar to that previously obtained using a RHO-speciWc ribo-
zyme in wild-type mice (Gorbatyuk et al., 2005). In
Fig. 2. Map of the rAAV vector. Expression of siRNA was driven by an
H1 promoter. Green Xuorescent protein (GFP) was expressed by the
hybrid CMV enhancer-chicken -actin (CBA) promoter. Localization of
siRNA301 was monitored by detection of humanized GFP (GFPh). The
region packaged in AAV was Xanked by the inverted terminal repeats of
AAV2 (TR). Viruses were psuedotyped by packaging into AAV-5 capsids.contrast, in RHO +/¡ mice AAV delivery of siRNA301 led
to a signiWcant reduction in both a- and b-wave maximum
amplitudes (Fig. 3b and c). At 1 month after injection, the
reduction of a-wave amplitude was 40% (p < 0.012) relative
to control eyes injected with an AAV vector expressing
irrelevant phospholamban siRNA. At 2 months, this reduc-
tion was over 50%, (p < 0.027). ERG b-wave amplitudes
were diminished as well. One month after injection, the b-
wave amplitude was 25% lower in experimental eyes com-
pared to controls (p < 0.027). After the second month, this
reduction increased to over 50% (p < 0.005).
Fig. 3. Expression of siRNA leads to reduction of a- and b-wave ampli-
tudes of the scotopic ERG. (a) a- and b-wave amplitudes of C57BL/6
RHO+/+ mice at 1 and 2 months after injection with an irrelevant siRNA
or with siRNA 301 into their right eyes (N D 9 in each group). Although
diminution in a- and b-wave amplitudes was observed, these diVerences
did not achieve statistical signiWcance. p values for a- and b-waves were
< 0.08 and <0.2 at 1 month and <0.08 and <0.12 at 2 months, respectively.
(b) A-wave amplitudes in eyes of RHO+/¡ mice injected with siRNA301
were about 40% lower compared to control eyes at 1 month after injec-
tion, p < 0.012 (N D 15 in each group). At 2 months after injection, the
amplitudes were diminished more signiWcantly (57%) compared to eyes
injected with control siRNA (p value <0.027). (c) Reduction of b-wave
amplitudes in eyes of RHO+/¡ mice injected with siRNA301 was 25% at
1 month after injection compared to eyes injected with control siRNA
(p < 0.027). At 2 months after injection, this reduction was more pro-
nounced (over 50%) in experimental eyes.
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RHO+/+ mice with no obvious visual phenotype and
RHO+/¡ mice were sacriWced for mRNA analysis 2
months after injection. Reverse transcription PCR was
used to detect levels of RHO transcripts, which were nor-
malized by dividing the band intensity of the RHO prod-
uct by the band intensity of -actin PCR product from
the same sample. Results were expressed as a ratio of the
normalized RHO level of the AAV-treated eyes to that of
the untreated eyes. Despite of the fact that we did not see
a signiWcant ERG diVerence between injected and unin-
jected eyes of RHO+/+ mice, the level of RHO mRNA
was diminished by 49% (p < 0.04) in siRNA301 treated
eyes (Fig. 4a). Delivery of AAV5 siRNA301 to RHO+/¡
retinas led to a reduction of the RHO mRNA level by
over 30% (p < 0.012) compared to mRNA extracted from
eyes injected with irrelevant siRNA (Fig. 4b). Therefore,
in wild-type mice, residual rhodopsin synthesis following
siRNA treatment supports an ERG response that is only
slightly diminished relative to control eyes, while in
RHO+/¡ mice, further reduction of rhodopsin expres-
sion led to a decrease in ERG amplitudes.
Fig. 4. Expression of siRNA301 in retinas of mice injected at P16 leads to
reduction of RHO mRNA. At 2 months after injection, the reduction of
RHO mRNA (normalized to -actin mRNA) was about 50% in RHO+/+
mice, p < 0.04 (N D 6 in each group) (a) and over 30% in RHO+/¡ mice,
p < 0.0076 (N D 5 in each group) (b). Bars represent the ratio of the nor-
malized rhodopsin mRNA level in the siRNA301-treated eyes to the nor-
malized rhodopsin mRNA values in the control eyes and are given in
percent.3.5. AAV5 siRNA301 reduced the steady state level of 
rhodopsin protein in mouse retinas
Expression of siRNA301 in the retina led to a decrease
in the level of rhodopsin protein as detected by Western
blot (Table 2). We compared the level of rhodopsin protein
in eyes of RHO+/¡ mice treated with siRNA301 with eyes
treated with an irrelevant siRNA. Densities of the opsin
bands in Western blots were normalized to the level of -
actin from the same samples. In this experiment, opsin
reduction was 60%, p < 0.013, compared to the control. We
infer that the remaining 30–40% of RHO protein was suY-
cient to support 40–50% of the ERG response, consistent
with the fraction of remaining rods (see below).
3.6. AAV-siRNA301 treatment causes thinning of the ONL 
in RHO+/¡ mice
In mice treated with siRNA301, we measured a reduc-
tion in the ONL thickness at 2 months post-injection
(Fig. 5). Expression of this RHO-speciWc siRNA resulted in
the reduction of the ONL thickness in the range of 53–86%
compared to eyes injected with AAV-expressing an irrele-
vant siRNA (p < 0.004). The region located within 1200m
of optic nerve head (ONH) was most aVected by siRNA301
Table 2
Rhodopsin protein reduction following siRNA or control injection
a Values (ratios of the intensity of the RHO band to the -actin band in
a Western blot) represent the content of rhodopsin protein in %. Experi-
ment was done in triplicate. Right eyes were injected with either siR-
NA301 or irrelevant (phospholamban) siRNA. Left eyes were uninjected.





siRNA301 40.4 § 10.6a 100 § 17.6 <0.0127
Irrelevant. siRNA 125.7 § 31.8 100 § 10.7 <0.445
Fig. 5. Expression of siRNA301 in the mouse retina causes reduction in
ONL thickness. Retinal nuclei were detected by propidium iodide stain-
ing. Retinas of six mice in each group were divided into 400 M sectors
starting from optic nerve head (ONH), and the thickness of ONL was
quantitated using the Zeiss Axiovision 4.4 software. Reduction in the
ONL thickness of mice injected with siRNA301 (heavy line) ranged from
53% to 86% across the full retina compared to retinas injected with the
control siRNA (thin line). The most aVected regions siRNA301 treated
retinas were in the inferior hemisphere, in the sector between 800 and
2000 m from the ONH and in the superior hemisphere 1200 m from the
ONH. (*p value <0.04, **p value <0.0097, ***p value <0.002).
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between 800 and 2000m from ONH and in the superior
hemisphere up to 1200m from the ONH was statistically
signiWcant. Analysis of ONL thickness and RHO protein
levels determined by Western blot, suggests that loss of rho-
dopsin from surviving cells, in addition to the loss of photo-
receptors, contributed to the 60% reduction of opsin
protein that we observed (Table 2).
4. Discussion
Allelic heterogeneity poses a serious problem for eVorts
to treat ADRP by sequence speciWc reagents. Additionally,
there are technical limitations to the designing ribozymes or
siRNAs speciWc for each of the RHO mutation. In the case
of ribozymes, there may be no cleavage sites near the sites
of mutations, while in the case of siRNA, a single nucleo-
tide change may not provide enough speciWcity to distin-
guish mutant from wild-type mRNA. To overcome these
diYculties, we and other groups are trying to design RNA
inhibitors that do not discriminate between mutant and
wild-type transcripts, but reduce the expression of both. To
be useful for therapy, these allele non-speciWc inhibitors will
need to be delivered along with a wild-type cDNA of RHO
that has been rendered resistant to the siRNA or ribozyme
through silent mutations. Our previous studies have been
based on the application of ribozymes to control expression
of the RHO gene by means of direct RNA cleavage. In this
paper, we extend this approach to include RISC-mediated
RNA interference as a Wrst step in the development of a
general strategy to replace RHO transcripts in living
animals.
RNA interference has been used by others to target the
expression of the RHO gene (Cashman, Binkley, & Kumar-
Singh, 2005; Kiang et al., 2005). Experiments conducted
in vitro and in the liver in vivo following hydrodynamic tail
vein injection of siRNA and a RHO-expressing plasmid
demonstrated that an siRNA can eVectively block RHO
expression in non-retinal cells or in retinal organ culture.
Tessitore et al. (2006), showed that mouse RHO mRNA
could be knocked down in the retina of a living rat. We
have now shown that endogenous rhodopsin protein (and
RNA) can be suppressed in the retina in vivo. SiRNA301
was created for use in a canine model of ADRP containing
T4R rhodopsin (Kijas et al., 2002). For in vivo validation of
this siRNA, we choose heterozygous RHO+/¡ mice as a
working model, because they already contain a 40% reduc-
tion in the level of rhodopsin protein. AAV delivered gene
expression was distributed across the full retina, although
the inferior hemisphere was transduced to a higher extent
than the superior retina. This region-speciWc transduction
was reXected in a greater decrease in the ONL thickness in
the inferior retina, suggesting that the regional delivery of
vector may be a critical factor for siRNA potency in vivo.
Expression of siRNA in vivo led to a reduction in the
visual response as reXected in diminished scotopic ERG a-
and b-wave amplitudes. However, over the two months ofanalysis, the rate of decline of the a- and b-waves was not
identical. A-wave amplitudes declined faster in response to
the expression siRNA301 in photoreceptors than did the b-
wave (Fig. 3c). The diVerence in the rate of the decline of a-
and b-wave amplitudes could be due to the compensatory
eVects occurring at the synaptic level between rods and rod
bipolar cells or due to the stabilization of the remaining
photoreceptors cells. An analogous and much more
detailed observation was reported by Richards, Emondi,
and Rohrer (2006) in response to light damage to the
mouse retina. We would expect siRNA delivered by AAV5
to be expressed in photoreceptor cells by the 1 month time
point (Auricchio et al., 2001). The fact that the ERG
response continues to decline suggests that photoreceptors
continue to degenerate during the second month.
The ERG data correlated with the reduction in the ONL
thickness of retinas injected with AAV-siRNA301 mea-
sured at 2 months after injection. ONL thinning was signiW-
cant overall (p value <0.04) but was not uniform along the
full retina, and ranged from 53% to 86% compared to the
control eye. The most dramatic reduction of the ONL
thickness was observed in the inferior hemisphere in a
region approximately 1200m away from ONH, where a
greater percentage of photoreceptors were transduced by
AAV. SiRNA301 led to the loss of more than 50% of the
photoreceptors from these retinas (Fig. 5). At this stage,
reduction of rhodopsin protein was 60–70%, and since this
level was normalized to -actin, this probably reXects
reduced rhodopsin production in remaining cells. It is hard
to explain the diVerence between the protein decrease and
the 30% reduction measured in mRNA, but the assays are
completely independent and have their own sources of vari-
ation. However, it is clear from these experiments that
RNA interference with siRNA can down-regulate expres-
sion of the RHO gene in vivo.
As the second step toward a generalized ADRP gene
therapy, the supplementation with wild type RHO will be
required. Designing an siRNA-resistant RHO gene should
not be a major impediment. Kiang et al. (2005) and Cash-
man et al. (2005) have demonstrated how this might be
done for RHO. The mouse-speciWcity of the RHO siRNAs
designed by Tessitore et al., was due to 4 mismatches with
the endogenous rat mRNA (Tessitore et al., 2006). A more
important issue is balancing the expression of the siRNA
and the replacement rhodopsin so that rhodopsin levels
remain suYciently high to sustain photoreceptors but not
so high that they become toxic (Tan et al., 2001). In addi-
tion, over-expression of shRNA has been shown to lead to
competition between shRNA and miRNAs for limiting cel-
lular factors required for the processing of various small
RNAs (Grimm et al., 2006). Consequently, over-expression
of shRNAs must also be avoided.
Another issue we need to explore is the time-frame for
ADRP therapy. Working with RHO+/¡ mice, we simply
validated the use of siRNAs delivered by AAV. The treat-
ment of a real ADRP mouse model, however, requires the
delivery of therapeutic agents early enough to prevent the
1208 M. Gorbatyuk et al. / Vision Research 47 (2007) 1202–1208massive loss of photoreceptor cells. Because of the rapid
course of retinal degeneration in many rodent models, the
intervention using RNA inhibitors (siRNAs or ribozymes)
may have to be initiated before substantial of retinal degen-
eration has begun. The appropriate timing may vary with
the model and the treatment.
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